Oppenheimer Maintains Perform on Editas Medicine, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains a Perform rating on Editas Medicine (NASDAQ:EDIT) and keeps the price target at $12.
June 18, 2024 | 4:46 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer analyst Jay Olson maintains a Perform rating on Editas Medicine and keeps the price target at $12.
The analyst's decision to maintain the Perform rating and the $12 price target suggests a neutral outlook on the stock. This indicates that the stock is expected to perform in line with the market, and there are no significant changes in the company's prospects according to the analyst.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100